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ABSTRACT The objective of this study was to characterize the etiological role of
human adenovirus (HAdV) serotypes in pediatric gastroenteritis. Using a case-control
design, we compared the frequencies of HAdV serotypes between children with 3
episodes of vomiting or diarrhea within 24 h and 7 days of symptoms (i.e., cases)
and those with no infectious symptoms (i.e., controls). Stool samples and/or rectal
swabs underwent molecular serotyping with cycle threshold (Ct) values provided by
multiplex real-time reverse transcription-PCR testing. Cases without respiratory symp-
toms were analyzed to calculate the proportion of disease attributed to individual
HAdV serotypes (i.e., attributable fraction). Between December 2014 and August
2018, adenoviruses were detected in 18.8% (629/3,347) of cases and 7.2% (97/1,355)
of controls, a difference of 11.6% (95% confidence interval [CI], 9.6%, 13.5%). In 96%
(95% CI, 92 to 98%) of HAdV F40/41 detections, the symptoms could be attributed
to the identified serotype; when serotypes C1, C2, C5, and C6 were detected, they
were responsible for symptoms in 52% (95% CI, 12 to 73%). Ct values were lower
among cases than among controls (P  0.001). HAdV F40/41, C2, and C1 accounted
for 59.7% (279/467), 17.6% (82/467), and 12.0% (56/467) of all typed cases, respec-
tively. Among cases, Ct values were lower for F40/41 serotypes than for non-F40/41
serotypes (P  0.001). HAdV F40/41 serotypes account for the majority of HAdV-
positive gastroenteritis cases, and when detected, disease is almost always attributed
to infection with these pathogens. Non-F40/41 HAdV species have a higher fre-
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quency of asymptomatic infection and may not necessarily explain gastroenteritis
symptoms. Real-time quantitative PCR may be useful in differentiating asymptomatic
shedding from active infection.
KEYWORDS molecular epidemiology, clinical findings, adenovirus, pediatric,
emergency, gastroenteritis
Human adenoviruses (HAdVs) are nonenveloped, double-stranded DNA virusesclassified into seven species (A to G). HAdVs are assigned to over 100 types, many
of which were initially defined based on neutralizing serology typing. The spectrum of
HAdV infection depends on the species and type of agent and the age and immune
status of the host, with clinical syndromes ranging from mild to severe respiratory,
gastrointestinal, or urinary tract disease to fulminant disseminated infections (1).
Serological surveys show that antibodies to HAdV serotypes 1, 2, and 5 are most
common in children. However, it has been over 35 years since F species serotypes were
identified as causing acute gastroenteritis (AGE) (2–5). HAdV serotypes belonging to
subgroups A, B, C, D, and G have been identified in patients with diarrhea; however,
their etiological roles are unclear (3). Molecular test interpretation is further compli-
cated by the high incidence of prolonged fecal shedding (6) and asymptomatic
infection by HAdV (6, 7). In a Chinese study that included 273 children with diarrhea
and 361 healthy controls, HAdVs were detected in 29% of cases and 7% of controls (3).
In another study, conducted in India, in which 1,053 stool specimens from children with
diarrhea and 1,035 asymptomatic control specimens were analyzed, 5% and 2% were
positive for HAdV 40 and 41, respectively (8). Thus, given these widely varying detection
rates in symptomatic and asymptomatic children, a better understanding of the
epidemiology of HAdV serotypes associated with pediatric AGE is needed.
MATERIALS AND METHODS
Study design, setting, and population. Children with AGE (i.e., cases) and asymptomatic controls
were recruited as part of a prospective cohort study (9). Research Ethics Board approvals were obtained
along with informed consent and assent, as appropriate.
Cases were recruited in the emergency departments (EDs) of two pediatric tertiary care institutions
in Alberta, Canada. AGE cases managed at home by caregivers, following a recommendation from a
province-wide, triage telephone advice resource operated by nurses (10), were asked if their contact
information could be shared with the study team. Those who agreed were contacted and recruited.
Cases met the following criteria: 18.0 years of age, 3 episodes of vomiting and/or diarrhea within
a 24-h period, and 7 days of symptoms (11). Children were excluded if they had been enrolled during
the prior 14 days, presented with an acute mental health concern, had a known neutrophil count of
1.0  109 neutrophils/liter, or needed emergent medical interventions.
Asymptomatic controls were recruited in the same EDs and in a public health clinic. Eligible controls
were 18.0 years old, agreed to provide a stool specimen, and were free of the following symptoms for
7 days: vomiting, diarrhea, fever, rhinorrhea, and cough. Data were collected by research assistants who
administered a structured questionnaire at enrollment and again 14 days later.
Objectives and outcome measures. The study’s primary objectives were to identify and compare
the frequencies of HAdV types detected between cases and controls and to assess the likelihood that
case AGE symptoms are due to the HAdV identified (i.e., attributable fraction [AF]). The AF quantifies the
proportion of patients in a cohort in whom a specific HAdV type was detected, whose AGE symptoms
are in fact due to that specific HAdV type. Secondary objectives were to compare stool viral concentra-
tions, codetected pathogens, and illness severity between HAdV 40/41 and non-40/41 cases.
Definitions. The estimation of the viral concentration in stool was based on the cycle threshold (Ct)
values determined using an in-house real-time reverse transcription-quantitative PCR (RT-qPCR) gastro-
enteritis virus panel (GVP) (12). Illness severity was quantified by employing the total-illness modified
Vesikari scale (MVS) score, which ranges from 0 to 20, with higher scores indicating more severe disease
(13, 14).
Specimen collection and laboratory methodology. (i) ED cases. Two flocked swabs (FLOQSwab;
Copan Italia, Italy) were inserted sequentially into the rectum and rotated 360° once. One swab was
placed into a dry, sterile tube, and the other was inserted into 2 ml of modified Cary-Blair transport
medium (FecalSwab; Copan Italia, Italy). Stool specimens were collected in sterile containers (catalog
number V302-F; Starplex Scientific Inc., Ontario, Canada). If a stool specimen was not provided before ED
discharge, caregivers obtained stool at home and samples were transported to the laboratory by couriers
within 24 hours of collection.
(ii) Home care cases. Stool collection kits containing two rectal swabs, a stool container, and
instructions were couriered to the home. Caregivers collected the first stool sample produced and
performed the rectal swabs at the same time.
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(iii) Controls. Stool specimens were collected in sterile containers (catalog number V302-F; Starplex
Scientific Inc., Ontario, Canada). If a stool specimen was not provided before ED/clinic discharge,
caregivers were requested to collect a specimen at home.
Specimen processing. All testing was performed by staff who were blind to clinical data.
(i) Culture. Upon receipt at the laboratory, enteric bacterial culture was performed on the stool
specimens and rectal swab specimens collected in modified Cary-Blair transport medium as previously
described (15).
(ii) Molecular diagnostics. Stool specimens were stored at 80°C until tested. Immediately before
nucleic acid extraction, stool specimens were thawed and aliquoted. Specimen preparation and nucleic
acid extraction were subsequently performed as previously described (16). Molecular testing was then
performed by employing the Luminex xTAG gastrointestinal pathogen panel (GPP) (Luminex Molecular
Diagnostics, Austin, TX, USA) (17) and an in-house RT-qPCR GVP as previously described (16).
The GPP is designed to detect adenovirus 40/41, Campylobacter, Clostridioides difficile, Cryptospo-
ridium, Entamoeba histolytica, Escherichia coli O157, enterotoxigenic Escherichia coli, Giardia, norovirus GI
and GII, rotavirus, Salmonella, Shiga toxin-producing Escherichia coli, Shigella, Vibrio cholerae, and Yersinia
enterocolitica. The in-house two-step RT-qPCR GVP includes a reverse transcription step using 5 l of
nucleic acid extracts and SuperScript II (Thermo Fisher Scientific, Burlington, ON, Canada), followed by
three simultaneous duplex qPCRs (the duplex format for generic HAdV and rotavirus, norovirus GI and
GII, and astrovirus and sapovirus) on a single run (18). This approach has high accuracy for a broad range
of HAdV serotypes with the exception of serotype 31 when it is present at low concentrations (19).
(iii) Adenovirus amplification and typing. All HAdV GPP-positive specimens were assumed to be
F40/41 (20) according to the manufacturer’s insert. Samples that tested HAdV positive by the GVP assay
and negative by the GPP were serotyped, as they were presumed to be non-F40/41. A primer set (21)
targeting hypervariable region 7 of the hexon gene that detects all known HAdV serotypes and allows
molecular serotype determination by sequence analysis was used for PCR amplification. The AmpliTaq
Gold fast PCR master mix (Thermo Fisher Scientific, USA) was combined with a final concentration of
0.5 M forward and reverse primers and 5 l of the template. Amplification was performed in a Veriti fast
thermal cycler (Applied Biosystems, USA) using a denaturation step at 95°C for 10 min, followed by 37
cycles of denaturation at 96°C for 3 s, annealing at 51°C for 3 s, and amplification at 68°C for 5 s. The final
extension step was performed at 72°C for 5 min. After gel electrophoresis and cleaning of the 640-bp PCR
product using the E.Z.N.A. gel extraction kit or the Cycle Pure kit (Omega Bio-Tek, Norcross, GA, USA), as
appropriate, we performed Sanger sequencing using the BigDye Terminator v3.1 cycle sequencing kit
and the BigDye XTerminator purification kit (Life Technologies) on the 3500xl genetic analyzer (ABI).
(iv) Bioinformatic and phylogenetic analyses. Sequence quality was analyzed using Sequencing
Analysis v6.0 (Applied Biosystems, USA), and sequences were compared to those in the nonredundant
NCBI database using BLAST (22) for species determination.
Statistical analysis. Participants were considered positive for a given pathogen if either the swab or
stool specimen tested positive using any assay. All positive results were assumed to be true positives,
except for Clostridioides difficile when detected in children 2 years of age, for which they were classified as
negative.
We performed multivariable logistic regression on case-control data to generate odds ratios (ORs) for
HAdV serotypes grouped by species to examine the association of detection with AGE symptoms. The
OR for each adenovirus species was adjusted for other adenovirus species detected in cases and controls,
adenovirus detections for which typing was not available (i.e., unsuccessful due to an inadequate viral
load in the specimen), codetected pathogens (astrovirus, norovirus, rotavirus, sapovirus, C. difficile, and
other bacteria and parasites), participant age (using standard and quadratic terms), geographic location
(Calgary, Edmonton, or other), and year and season of enrollment. Because many adenovirus serotypes
can cause respiratory symptoms, and since control participants were required to have no infectious
symptoms, cases with rhinorrhea or cough (i.e., respiratory symptoms) were excluded from this analysis.
For each detected adenovirus species, the AFs and 95% confidence intervals (CIs) were calculated by
employing the ORs derived from the above-mentioned model.
Two-tailed P values of 0.05 were considered statistically significant. Analyses were conducted using
SPSS version 25.0 (IBM Corp., Armonk, NY).
RESULTS
Between December 2014 and August 2018, 1,355 controls and 3,347 cases were
enrolled (Fig. 1). Overall, 18.8% (629/3,347) of the cases and 7.2% (97/1,355) of the
controls were positive for HAdV (Table 1). The agreement between stool specimens and
rectal swabs among AGE cases, assessed using the kappa statistic, was substantial (0.78
[95% CI, 0.75, 0.82]) (23). Positivity peaked among AGE cases between 12 and
18 months and among controls between 18 and 24 months of age (Fig. 2).
Primary outcome: adenovirus typing. Typing results were available for 74.2%
(467/629) of positive cases, which exceeded the rate among controls (74.2% versus
43.3% [P  0.001]). HAdV F40/41 accounted for the majority (59.7%; 279/467) of all
typed adenovirus AGE cases (Table 2). The most common typeable HAdV serotype
among controls was C2 (13/42; 31.0%). The only other common serotypes among cases
were C1 and C2, both of which were more commonly detected in the controls (Fig. 3).
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Respiratory symptoms were present in 50.0% (1,365/2,728) of the AGE cases for
whom they were recorded. Among those without respiratory symptoms, 24.6% (335/
1,363) were positive for HAdV, and serotyping was available for 51.0% (171/335) (Table
2). Multivariable logistic regression demonstrated that HAdV species F (40/41) and C
(1/2/5/6) detection was associated with AGE (ORs, 24.9 [95% CI, 13.0, 47.7] and 2.1 [95%
FIG 1 Study participants.




cases (n  2,718)
HAdV-positive





controls (n  1,258)
HAdV-positive




Median age (mo) (IQR) 19.7 (10.1, 45.2) 16.5 (11.1, 30.6) 0.002 12.1 (4.1, 31.1) 18.2 (12.1, 38.3) 0.001
No. of males (%) 1,437 (52.9) 369 (58.7) 0.009 665 (52.9) 57 (58.8) 0.29
No. of cases in enrollment season (%) 0.006 0.20
January–March 686 (25.2) 142 (22.6) 0.17 222 (17.6) 25 (25.8) 0.06
April–June 879 (32.3) 172 (27.3) 0.02 298 (23.7) 22 (22.7) 0.90
July–September 536 (19.7) 144 (22.9) 0.08 380 (30.2) 23 (23.7) 0.21
October–December 617 (22.7) 171 (27.2) 0.02 358 (28.5) 27 (27.8) 0.91
No. of HAdV-positive cases (%)
Overall NA 629 (100) NA 97 (100) NA
GPP positive NA 271 (43.1) NA 10 (10.3) NA
GVP positive NA 629 (100) NA 97 (100) NA
GPP positive only NA 0 (0) NA 0 (0) NA
GVP positive only NA 358 (56.9) NA 87 (89.7) NA
Both GPP and GVP positive NA 271 (43.1) NA 10 (10.3) NA
Median Ct value (IQR) NA 22.8 (14.5, 32.7) NA 32.3 (29.5, 34.2) NA
aHAdV, human adenovirus; GPP, gastrointestinal pathogen panel; GVP, gastroenteritis virus panel; NA, not applicable; Ct, cycle threshold.
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CI, 1.1, 3.8], respectively). The AF for F40/41 was 96% (95% CI, 92.3 to 97.7%), whereas
that for C1/2/5/6 was 51.7% (95% CI, 11.5 to 73.4%). An association between AGE and
detection of species A and B could not be confirmed.
Secondary outcomes. Stool Ct values were lower among HAdV-positive cases
(median, 22.8 [interquartile range {IQR}, 14.5, 32.7]) than among HAdV-positive controls
(median, 32.3 [IQR, 29.5, 34.2] [P  0.001]) (Fig. 4A). The median Ct values of the positive
case and control specimens that could not be typed were higher than those of
specimens that were typeable (34.4 [IQR, 32.9, 35.7] versus 18.3 [IQR, 13.2, 26.0]
[P  0.001] among cases and 34.0 [IQR, 32.4, 35.1] versus 29.5 [IQR, 25.4, 31.3]
[P  0.001] among controls). Among all cases (n  629), the median Ct values were
lower among HAdV F40/41-positive specimens than among non-F40/41-positive spec-
imens (Fig. 4B).
Codetection of adenovirus and other pathogens occurred in 16.8% (47/279) of cases
in whom F40/41 was detected and in 50.5% (95/188) of those with non-F40/41 HAdV
(difference, 33.7% [95% CI of the difference, 42.1%, 24.8%]) (Table 3). The overall
codetection rate was higher among cases (250/629; 39.8%) than among controls (21/97;
21.7%) (difference, 18.1% [95% CI of the difference, 7.6%, 26.5%]).
Symptom severity. Among HAdV cases (n  629), the total illness severity scores
did not differ between those with HAdV F40/41 and those with non-F40/41 (P  0.17)
(Table 4). For both HAdV F40/41 and non-F40/41 cases, total MVS scores correlated
inversely with Ct values (lower values indicate higher viral loads), indicating that
children with higher viral loads had more severe disease (P  0.0001 and P  0.06,
respectively) (Fig. 5).
DISCUSSION
This study confirms the importance of HAdV as an enteropathogen and the role
of HAdV F40/41 serotypes, which accounted for nearly 60% of all HAdV-positive
cases. Among AGE cases who had HAdV species F40/41 detected, disease could
almost always (AF  96%) be attributed to infection with these pathogens. When
HAdV species C serotypes were detected, only half (AF  52%) of illnesses could be
attributed to them. We could not confirm any association between AGE symptoms
and the detection of HAdV species A or B. When combined with Ct data showing
overall lower HAdV concentrations in controls than in cases, our findings demon-
strate the need for caution when attributing gastroenteritis symptoms to HAdV
species C serotypes.
We detected HAdV F40/41 in 8.3% of all gastroenteritis cases. This finding confirms
FIG 2 Human adenovirus distributions across age groupings in children with acute gastroenteritis (cases
and healthy controls). Numbers of participants in each age group are as follows: 0 to 6 months, 359
cases and 448 controls; 6 to 12 months, 669 cases and 178 controls; 12 to 18 months, 584 cases and
146 controls; 18 to 24 months, 337 cases and 164 controls; 24 to 60 months, 894 cases and 251
controls; 60 months, 504 cases and 168 controls. The denominator reflects the entire cohort of controls
and cases tested for human adenovirus.
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previous reports (16, 24); however, these studies lacked a control cohort to differentiate
infection from detection. In a multisite U.S. study that employed a control cohort, HAdV
was identified in 12% of children with AGE and just 2% of controls (25). The low
detection rate among controls relative to our study may reflect their detection of only
HAdV 41, which accounted for a minority of detections among our controls. Although
a U.S.-based study focused on children 2 years of age that tested only for HAdV
FIG 3 Adenovirus serotype distribution. (A) Distribution of adenovirus serotypes among all included
acute gastroenteritis cases (n  3,347) and controls (n  1,355). (B) Distribution of adenovirus serotypes
among typeable acute gastroenteritis cases (n  467) and controls (n  42) who tested positive for
adenovirus.
FIG 4 Box plot of stool cycle threshold (Ct) values of adenovirus. (A) Adenovirus-positive acute gastroenteritis cases (n  516) (median, 22.8 [IQR, 14.6, 32.7])
versus adenovirus-positive controls (n  97) (median, 32.3 [IQR, 29.5, 34.1]). Significance was tested by a Mann-Whitney U test (two-sided unadjusted P value
of 0.001). (B) Adenovirus F40/41-positive acute gastroenteritis cases (n  229) (median, 13.8 [IQR, 11.5, 17.3]) versus non-F40/41-positive cases (n  153)
(median, 25.8 [IQR, 20.9, 30.9]). Significance was tested by a Mann-Whitney U test (two-sided unadjusted P value of 0.001). (C) Adenovirus-positive acute
gastroenteritis cases with monodetections (n  250) (median, 17.4 [IQR, 13.0, 26.9]) versus adenovirus-positive cases with codetections (n  266) (median, 30.4
[IQR, 20.3, 33.7]). Significance was tested by a Mann-Whitney U test (two-sided unadjusted P value of 0.001).
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F40/41 reported no statistically significant difference between AGE cases (23%) and
controls (16%) (26), these results were skewed by a single site that detected adenovirus
in 40% of cases and controls.
Few studies have specified HAdV subgroups and serotypes among children with
AGE. A study of children in Thailand most commonly identified subgroups C (41%), F
(29%), and B (21%) (2). HAdV F41 was the predominant serotype (22%), followed by
HAdV C2 (18%), B3 (15%), C1 (13%), and F40 (6%). In our study, HAdV subgroup C was
TABLE 3 Codetection among human adenovirus 40/41 and non-40/41 acute gastroenteritis casesa
Codetected pathogen
No. of cases (%)
Difference (%) (95% CI)d P valuedOverallc (n  629) F40/41 (n  279) Non-F40/41 (n  188)
Any codetection 250 (39.7) 47 (16.8) 95 (50.5) 33.7 (42.1, 24.8) 0.001
Any virus codetection 225 (35.8) 36 (12.9) 89 (47.3) 34.4 (42.6, 25.8) 0.001
Norovirus 119 (18.9) 14 (5.0) 51 (27.1) 22.1 (29.5, 15.1) 0.001
Sapovirus 62 (9.9) 15 (5.4) 27 (14.4) 10.4 (16.7, 4.9) 0.001
Rotavirus 51 (8.1) 9 (3.2) 16 (8.5) 5.3 (10.7, 0.7) 0.02
Astrovirus 15 (2.4) 2 (0.7) 6 (3.2) 2.5 (6.5, 0.4) 0.07
Any bacterium codetection 31 (4.9) 10 (3.6) 9 (4.8) 1.2 (5.9, 2.8) 0.63
Clostridioides difficileb 10 (1.6) 5 (1.8) 2 (1.1) 0.7 (3.5, 2.6) 0.71
Campylobacter spp. 2 (0.3) 1 (0.4) 0 (0) 0.4 (2.2, 2.3) 0.99
Enterotoxigenic Escherichia coli 2 (0.3) 1 (0.4) 1 (0.5) 0.1 (3.0, 1.8) 0.99
Salmonella spp. 3 (0.5) 1 (0.4) 2 (1.1) 0.7 (3.9, 1.4) 0.57
Shiga toxin-producing E. coli 3 (0.5) 1 (0.4) 0 (0) 0.4 (2.2, 2.3) 0.99
Shigella spp. 1 (0.2) 1 (0.4) 0 (0) 0.4 (2.2, 2.3) 0.99
Aeromonas spp. 6 (1.0) 0 (0) 5 (2.7) 2.7 (6.4, 0.3) 0.01
Yersinia spp. 1 (0.2) 0 (0) 0 (0) NA NA
Any parasite codetection 4 (0.6) 2 (0.7) 0 (0) 0.7 (1.9, 2.9) 0.52
Cryptosporidium 1 (0.2) 0 (0) 0 (0) NA NA
Entamoeba 1 (0.2) 1 (0.4) 0 (0) 0.4 (2.2, 2.3) 0.99
Giardia 2 (0.3) 1 (0.4) 0 (0) 0.4 (2.2, 2.3) 0.99
aParticipants may have had more than 1 codetected pathogen.
bChildren 2.0 years of age in whom C. difficile was detected were considered negative and are not reported in this table.
cThe denominator included all cases that tested positive for adenovirus.
dComparison of serogroup F40/41 versus non-F40/41 HAdVs.
TABLE 4 Human adenovirus serotypes and acute gastroenteritis illness severitya
Parameter
HAdV F40/41 (n  279) HAdV non-F40/41 (n  188)
% difference





Median age (mo) (IQR) 279 17.1 (10.8, 30.7) 188 15.3 (10.5, 25.4) 1.5 (0.4, 3.5) 0.11
No. of males (%) 279 170 (60.9) 188 109 (58.0) 3.0 (6.3, 12.3) 0.56
No. of children with vomiting (%) 273 249 (91.2) 182 152 (83.5) 7.7 (1.2, 14.7) 0.02
Median no. of vomiting episodes (IQR)b 257 4 (3, 7) 174 4 (2, 7) 0 (1, 1) 0.97
Median vomiting duration (h) (IQR) 257 105.1 (54.3, 158.9) 174 60.4 (11.8, 111.5) 38.3 (24.6, 52.3) 0.001
No. of cases with diarrhea (%) 274 262 (95.6) 184 155 (84.2) 11.4 (5.5, 18.0) 0.001
Median no. of diarrhea episodes (IQR)b 257 6 (4, 9) 173 4 (2, 6) 2 (1, 3) 0.001
Median diarrhea duration (h) (IQR) 257 151.1 (94.4, 198.0) 174 115.4 (48.0, 192.0) 31.7 (12.0, 50.4) 0.001
No. of cases with isolated vomiting (%) 273 12 (4.4) 182 29 (15.9) 11.5 (18.2, 5.7) 0.001
No. of cases with isolated diarrhea (%) 274 24 (8.8) 184 30 (16.3) 7.6 (14.5, 1.1) 0.02
No. of cases with both vomiting and diarrhea (%) 269 233 (86.6) 178 119 (66.9) 19.8 (11.5, 28.1) 0.001
No. of cases with fever (%)c 267 88 (33.0) 180 131 (72.8) 39.8 (48.2, 30.4) 0.001
No. of cases with respiratory symptoms (%) 235 121 (51.5) 155 98 (63.2) 11.7 (21.7, 1.3) 0.03
No. of cases with ED visit after enrollment (%) 257 31 (12.1) 174 21 (12.1) 0.01 (6.4, 7.0) 0.99
No. of cases receiving intravenous fluid (%) 260 44 (16.9) 177 31 (17.5) 0.6 (8.4, 6.8) 0.90
No. of hospitalizations (%) 258 14 (5.4) 175 12 (6.9) 1.4 (7.0, 3.4) 0.68
Median MVS score (IQR) 257 13.0 (11.0, 15.0) 173 12.0 (10.0, 15.0) 0 (0, 1.0) 0.17
aED, emergency department; MVS, modified Vesikari scale; HAdV, human adenovirus.
bMaximal number of episodes in a given 24 h.
cFever was defined as a rectal temperature of 38.0°C. Temperatures were adjusted for the location of measurement: 1.1°C was added to axillary temperatures, and
0.6°C was added to oral temperatures.
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the leading non-F40/41 HAdV subgroup detected, but the role of serotypes in this
subgroup warrants further evaluation considering the low AF. While we also could not
confirm any association between AGE and detection of HAdV species A or B, our
analysis was impacted by the small number of such detections.
FIG 5 Scatterplots showing the relationship of adenovirus stool cycle threshold (Ct) values and modified Vesikari scale scores with a fitted linear regression line.
(A) Adenovirus serotype F40/41 (n  218) (Pearson correlation coefficient, 0.28; P  0.0001). (B) Adenovirus non-F40/41 serotypes (n  144) (Pearson
correlation coefficient, 0.16; P  0.06).
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In Fig. 4, we used Ct values to clarify the contributions of specific pathogens.
RT-qPCR Ct values represent the number of PCR cycles required for the amplification
curve to intersect the threshold line, as a relative measure of the target concentration
in the PCR. The higher the starting concentration of the target, the lower the Ct value.
Thus, Ct values are inversely proportional to viral loads and provide a semiquantitative
measure of the viral concentration in a sample. However, the assay itself and other
factors within the sample matrix can affect RT-qPCR efficiency, thereby influencing the
Ct values. Although a case-control study conducted in China reported no significant
differences in HAdV concentrations between cases and controls, suggesting that this
value alone cannot differentiate between infection and asymptomatic shedding, the
study was limited by a very small sample size (3). In a larger U.S.-based study, Ct values
differed between groups (P  0.0001), particularly among those with HAdV as the only
detected pathogen (26). As depicted in Fig. 4, we found that Ct values, when HAdVs
were detected, were lower among cases than among controls (Fig. 4A), lower for HAdV
F40/41 than for non-40/41 HAdV (Fig. 4B), and lower for monodetections than for
codetections (Fig. 4C).
Our study cannot rule out the possibility that detection represents long-term intermit-
tent or asymptomatic shedding of HAdV species (6, 7), and thus, we cannot confirm with
certainty the etiological role in childhood gastroenteritis of the HAdV species detected.
However, our findings indicate that when HAdV F40/41 species are detected in children
with AGE, the symptoms can be attributed to these pathogens with reasonable confidence,
which would be improved if the signal generated has a low Ct value and if other plausibly
causative agents are absent. On the other hand, our results support the notion that when
non-F40/41 HAdVs are detected in children with AGE, they should not routinely be
assumed to be causative. When clinically indicated, the use of quantitative PCR may prove
to be a useful adjunct to clarify the role played by HAdV in children with AGE by
differentiating asymptomatic shedding from active infection.
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